Market Cap (In USD)
31.06 Million
Revenue (In USD)
-
Net Income (In USD)
-10.23 Million
Avg. Volume
143.97 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.71-2.35
- PE
- -2.12
- EPS
- -0.4
- Beta Value
- 0.993
- ISIN
- US75989R1077
- CUSIP
- 75989R107
- CIK
- 1574094
- Shares
- 36546800.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Shaun R. Bagai
- Employee Count
- -
- Website
- https://renovorx.com
- Ipo Date
- 2021-08-26
- Details
- RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
More Stocks
-
IVZ
-
CCZ
-
WEGYF
-
EGDD
-
SP8
-
TLDE
-
0TMVFive9, Inc.
0TMV
-
IMMImmutep Limited
IMM